BIIB, Elan submit Antegren BLA

As expected, Biogen Idec (BIIB) and ELN submitted a BLA to the FDA for Antegren natalizumab to treat multiple sclerosis (MS). The BLA includes undisclosed one-year data from their ongoing two-year Phase III trials in about 2,100 patients. The companies plan to submit an MAA in Europe for the MS indication by the end of the quarter. ...